At what enterprise value was QSCAN GROUP acquired in 2020?

During the acquisition of QSCAN GROUP by INFRATIL in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of QSCAN GROUP when it was acquired by INFRATIL?

The estimated EV/EBITDA multiple for QSCAN GROUP is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was QSCAN GROUP acquired by INFRATIL?

QSCAN GROUP was acquired by INFRATIL in 2020.

What was the revenue of QSCAN GROUP at the time of the deal?

The revenue of QSCAN GROUP at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of QSCAN GROUP during the acquisition?

QSCAN GROUP's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the QSCAN GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the QSCAN GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://infratil.com/news/completion-of-acquisition-of-qscan/

← DATABASE

Home Database Healthcare & PharmaQSCAN GROUP

10/2020

QSCAN GROUP acquired by INFRATIL

AUSTRALIA Health Providers / Outpatient Care / Radiology EV 500M - 1.5b EUR

Context

Infratil, in partnership with MGIF, acquired a majority stake in Qscan Group from Quadrant Private Equity (QPE) and existing doctor shareholders. The transaction valued the entire group at an enterprise value of AUD 735 million. The deal was structured to provide Infratil with a platform in the high-growth diagnostic imaging market, characterized by aging demographics and the increasing clinical importance of early cancer detection. The acquisition was funded through Infratil's existing debt facilities and cash proceeds from previous divestments, reflecting a shift in their portfolio towards healthcare infrastructure.

QSCAN GROUP, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Qscan is a leading Australian diagnostic imaging provider, specializing in high-complexity services such as PET-CT and oncology imaging. At the time of the deal, it operated over 70 clinics across Australia, including 10 oncology clinics, and was a primary provider for hospital-based radiology services.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
11/2020	ARDIAN	INOVIE GROUP	FRANCE	Labs (Biology)
11/2020	L CATTERTON	ALLIANCE ANIMAL HEALTH	UNITED STATES	Vet Clinics
10/2020	THE VISTRIA GROUP / CENTERBRIDGE PARTNERS	HELP AT HOME	UNITED STATES	Nursing Homes
10/2020	KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS	ELSAN	FRANCE	Clinics / Hospitals
09/2020	EQT PARTNERS	COLISÉE	FRANCE	Nursing Homes
09/2020	VAM INVESTMENTS	DEMENEGO	ITALY	Ophthalmology
07/2020	BIOGROUP	LABORIZON	FRANCE	Labs (Biology)
07/2020	ORPEA	BRINDLEY HEALTHCARE	IRELAND	Nursing Homes
06/2020	ASKLEPIOS KLINIKEN	RHÖN-KLINIKUM	GERMANY	Clinics / Hospitals
03/2020	ORPEA	TLC GROUP	IRELAND	Nursing Homes

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 100M - 200M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of QSCAN GROUP by INFRATIL are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: qscan group

Acquirer: infratil